Published in Semin Arthritis Rheum on March 11, 2010
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis (2011) 1.42
Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Clin Rheumatol (2011) 1.42
Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther (2010) 1.38
Biologic therapy for autoimmune diseases: an update. BMC Med (2013) 1.23
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis (2012) 1.13
[Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis]. Z Rheumatol (2012) 1.06
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther (2011) 1.05
Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics (2014) 0.95
Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol (2013) 0.93
Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. PLoS One (2014) 0.89
An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology (Oxford) (2011) 0.88
Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int (2014) 0.88
Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. Health Qual Life Outcomes (2014) 0.88
Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord (2012) 0.87
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther (2015) 0.80
Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Res Ther (2010) 0.80
Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol (2015) 0.78
Selective inhibition of CDK7 ameliorates experimental arthritis in mice. Clin Exp Med (2014) 0.77
Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. Biomed Res Int (2015) 0.77
Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Ther Clin Risk Manag (2015) 0.77
Can Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis? Front Med (Lausanne) (2017) 0.75
Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. Int J Rheumatol (2017) 0.75
Abatacept: A Review in Rheumatoid Arthritis. Drugs (2017) 0.75
[Is it possible to compare different studies on efficacy of biologicals in patients with rheumatoid arthritis? : mixed treatment comparison as a new tool for indirect comparison of clinical studies]. Z Rheumatol (2011) 0.75
Tocilizumab (Actemra). Hum Vaccin Immunother (2017) 0.75
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum (2008) 19.80
Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol (2007) 13.46
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum (2004) 7.13
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol (2009) 6.00
Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med (2004) 5.69
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum (2002) 5.57
Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol (2007) 5.23
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med (2015) 4.49
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet (2002) 3.67
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials (2007) 3.29
Incidence of retinoblastoma in children born after in-vitro fertilisation. Lancet (2003) 3.22
Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci (2007) 3.16
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum (2004) 2.99
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health (2011) 2.88
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther (2008) 2.87
External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One (2007) 2.70
The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol (2008) 2.60
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum (2009) 2.55
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Hip fracture in women without osteoporosis. J Clin Endocrinol Metab (2005) 2.35
Progression of radiographic hip osteoarthritis over eight years in a community sample of elderly white women. Arthritis Rheum (2004) 2.32
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29
Effect of Mindfulness-Based Stress Reduction in rheumatoid arthritis patients. Arthritis Rheum (2007) 2.23
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res (2004) 2.23
Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol (2003) 2.20
The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum (2007) 2.16
Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin (2004) 2.11
Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 2.10
Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum (2004) 2.01
Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol (2006) 2.01
Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc (2002) 1.97
Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum (2003) 1.93
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res (2004) 1.93
Circulating 25-hydroxyvitamin D levels and frailty status in older women. J Clin Endocrinol Metab (2010) 1.93
How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum (2002) 1.91
Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum (2002) 1.86
Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed? Ann Intern Med (2009) 1.81
Objective physical activity measurement in the osteoarthritis initiative: Are guidelines being met? Arthritis Rheum (2011) 1.81
Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med (2012) 1.78
Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit Care Med (2005) 1.77
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol (2013) 1.77
Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis (2010) 1.76
Prevalence of hip symptoms and radiographic and symptomatic hip osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol (2009) 1.75
Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. J Rheumatol (2007) 1.74
Back pain exacerbations and lost productive time costs in United States workers. Spine (Phila Pa 1976) (2006) 1.72
Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol (2005) 1.70
Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics (2004) 1.68
Content validity of patient-reported outcome measures: perspectives from a PROMIS meeting. Qual Life Res (2011) 1.68
Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach. Qual Life Res (2006) 1.68
Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol (2002) 1.63
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int (2008) 1.56
Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum (2003) 1.56
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum (2002) 1.55
Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum (2002) 1.55
Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis (2007) 1.55
Surgical menopause and nonvertebral fracture risk among older US women. Menopause (2012) 1.52
Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med (2002) 1.48
The influence of methodologic quality on the conclusion of a landmark meta-analysis on thrombolytic therapy. Int J Technol Assess Health Care (2002) 1.48
Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials (2013) 1.47
Chemoreduction for retinoblastoma. Arch Ophthalmol (2003) 1.46
Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy (2012) 1.41
Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum (2003) 1.41
Percutaneous coronary intervention with off-site cardiac surgical backup. Am J Cardiol (2008) 1.40
Core outcome domains for clinical trials in non-specific low back pain. Eur Spine J (2015) 1.40
Racial differences in rate of decline in bone mass in older men: the Baltimore men's osteoporosis study. J Bone Miner Res (2005) 1.40
Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum (2005) 1.39
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis (2010) 1.38
Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res (2004) 1.38
Very low prevalence of hip osteoarthritis among Chinese elderly in Beijing, China, compared with whites in the United States: the Beijing osteoarthritis study. Arthritis Rheum (2002) 1.36
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol (2007) 1.35
Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol (2007) 1.33
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis (2012) 1.31
Assessing physical activity in persons with knee osteoarthritis using accelerometers: data from the osteoarthritis initiative. Arthritis Care Res (Hoboken) (2010) 1.30
Racial differences in bone mineral density in older men. J Bone Miner Res (2003) 1.30
Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab (2003) 1.30
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis (2009) 1.29
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther (2012) 1.29
Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol (2005) 1.28
Higher risk of multiple falls among elderly women who lose visual acuity. Ophthalmology (2004) 1.27
Characterization of individual radiographic features of hip osteoarthritis in African American and White women and men: the Johnston County Osteoarthritis Project. Arthritis Care Res (Hoboken) (2010) 1.25
Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. J Rheumatol (2003) 1.25
Treatment of ureteral and renal stones: a systematic review and meta-analysis of randomized, controlled trials. J Urol (2012) 1.24
The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol (2004) 1.22
Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum (2009) 1.21
Body mass index is positively associated with bone mineral density in US older adults. Arch Osteoporos (2014) 1.21
Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol (2009) 1.19
Quality of osteoarthritis management and the need for reform in the US. Arthritis Care Res (Hoboken) (2010) 1.17
OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. J Rheumatol (2007) 1.16
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res (2005) 1.16
Height loss in older women: risk of hip fracture and mortality independent of vertebral fractures. J Bone Miner Res (2012) 1.15